Vermont Alliance For Innovation On Maternal Health

presents



Care of Pregnant and Postpartum People with Substance Use Disorder Patient Safety Bundle







Disclosures

This webinar is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award for the Alliance for Innovation on Maternal Health. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.









Grounding the Work










Vermont's Landscape -



Substance	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Alcohol	3,639	3,635	3,461	3,244	3,240	3,270	2,966	2,328	2,251	2,281
Cannabis	1,302	1,269	1,160	1,133	1,138	959	858	572	594	531
Heroin/Opioids	5,420	6,084	6,456	6,605	6,594	6,178	5,724	5,629	5,335	4,844
Stimulants/Other	461	497	474	516	713	816	837	684	844	1,009

Vermont Department of Health

Source: Substance Abuse Treatment Information System (SATIS).












Vermont's Landscape -

Type of Substance Use Disorder Treatment Received By Clients in Fiscal Years 2022 & 2023

2022 2023



Note: Clients may receive more than one type of treatment in the year

State Fiscal Year	Outpatient	Intensive Outpatient	Residential	Case Management	Hub/MOUD	Total Clients
2022	3,489	533	1,766	1,364	4,527	9,024
2023	3,368	527	1,859	1,256	4,197	8,665

Vermont Department of Health

Source: Substance Abuse Treatment Information System (SATIS).











Vermont's Maternal Mortality Review Data

- Since 2012, 43% of perinatal deaths in Vermont were the result of accidental overdose. Substance misuse contributed to a significant majority of overall deaths.
- Of the 8 maternal deaths reviewed by the panel since 2021, all were related to opioid misuse – 7 were directly caused by overdose and one by endocarditis due to IV drug use.












A deeper look into timing -









From the Newborn Lens -




Figure 6: The proportion of pregnant individuals with an OEN receiving treatment with MOUD during the current pregnancy by medication type, 2019 to 2023. Receiving methadone MOUD (dark blue), receiving buprenorphine MOUD (light blue), no MOUD treatment reported (grey).

Evaluation and Report of Improving Care of Opioid-Exposed Newborns, 2024









Partners In This Work

Perinatal Substance Use
 Community Education
 [OD2A/CDC]

Maternal Mortality Review Panel [MMRP/CDC]



Regional Collaboration Planning with the 3 NE PQCs and NNEPQIN [Medicaid]



- Alliance for Innovation on Maternal Health Patient Safety Bundles [AIM/HRSA]
- Perinatal Mood Disorders
 Systems Support [Perinatal CARES/HRSA]
- Maternal Health Innovation Grant [HRSA]

- Neonatal Clinical Skills Training and Community Outreach [Medicaid]
- Hospital and Community Perinatal Reports [Medicaid]
- Addressing Systems of Care for Perinatal Substance Use & the Child Welfare System [IDTA/Medicaid]
- Clinical Care & Community Services Integration (PQC/CDC)









Clinical Practice Assessment

October 2024-January 2025



Screening: Clinic Assessment Data

100% of practices report screening perinatal



Screening: Clinic Assessment Data

First Prenatal Appointment

<u>Screening Topic</u>	Percentage
Tobacco	84.6
Alcohol	92.3
Cannabis	92.3
SUD	92.3
Mental Health- Depression	92.3
Mental Health- Anxiety	92.3
Mental Health- Other	100.0
SDoH	92.3
Interpersonal Violence	100.0

Postpartum – OB Clinic


<u>Screening Topic</u>	Percentage
Tobacco	23.1
Alcohol	23.1
Cannabis	23.1
SUD	30.8
Mental Health- Depression	61.5
Mental Health- Anxiety	61.5
Mental Health- Other	53.8
SDoH	38.5
Interpersonal Violence	23.1








Referrals: Clinic Assessment Data



Referrals: Clinic Assessment Data



- Nurse Home Visiting
- WIC
- Recovery Supports (Recovery Center, Turning Points, Peer Support)
- Parenting Support (Parent Child Center)
- Transportation
- Other Programs (AA, Support groups, etc)






- Help Me Grow
- CIS- Early Intervention
- Community Empaneled Team (CHARM/CRT)
- Financial Supports (Reach Up, Fuel, etc)
- Case Management Services





Clinic Assessment Data



Barriers to effective referral systems:

- Not all referrals are listed in the same place
- Not integrated into EMR
- Hard to tell if referral was successful
- Referral process paperwork is cumbersome









Areas of Focus -









Screening & Testing -

- NIDA & Screening tools
- Biochem testing (adult & newborn)
- Related infectious dx testing recommendations
- Referral Pathways
- Resource Mapping
- Prenatal Care Checklist

Community linkages & Referrals:

- Prenatal HMG referral
 - Family Care Plan (POSC)
 - Assessments completed by HH
- Feedback loops
- Each OB Practice/Hospital having a template that refers to local resources









Protocols/Guidelines -

- Prenatal
- Hospital
- Postpartum
- Reporting to DCF
- Naloxone Distribution









Patient Education –

- Why MOUD treatment?
- Family Care Plan
- What to Expect at Delivery
- DCF Reporting
- Universal Postpartum Naloxone
 Distribution

Health Care Provider Education -

- Prenatal checklist, Naloxone Rx
- Delivery planning
- Inpatient period: pain management, initiation of MOUD for active use, PP follow up care planning, nicotine replacement
- Family Care Plan
- DCF Reporting
- Stigma & Bias
- Trauma-informed Care
- Informed Consent









AIM Resources

- Upcoming Webinar: June 11th
 - The Inpatient Setting: Substance Use Treatment, Supportive Protocols, and Care of the Newborn
- All webinars are recorded and available
- Fall Webinar Schedule Coming Soon







